These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 25000217)

  • 1. An update on the use of melatonin as a stroke therapeutic.
    Gonzales-Portillo GS; Lozano D; Aguirre D; Reyes S; Borlongan CV; Tajiri N; Kaneko Y
    Minerva Med; 2015 Jun; 106(3):169-75. PubMed ID: 25000217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin-based therapeutics for neuroprotection in stroke.
    Shinozuka K; Staples M; Borlongan CV
    Int J Mol Sci; 2013 Apr; 14(5):8924-47. PubMed ID: 23698756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin as an Antioxidant for Stroke Neuroprotection.
    Watson N; Diamandis T; Gonzales-Portillo C; Reyes S; Borlongan CV
    Cell Transplant; 2016; 25(5):883-91. PubMed ID: 26497887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin, shedding new light on darkness.
    Miskovitz P
    Crit Care Med; 2008 Jan; 36(1):333-4. PubMed ID: 18158442
    [No Abstract]   [Full Text] [Related]  

  • 5. Melatonin and its receptors: a new class of sleep-promoting agents.
    Doghramji K
    J Clin Sleep Med; 2007 Aug; 3(5 Suppl):S17-23. PubMed ID: 17824497
    [No Abstract]   [Full Text] [Related]  

  • 6. Melatonin treatment following stroke induction modulates L-arginine metabolism.
    Nair SM; Rahman RM; Clarkson AN; Sutherland BA; Taurin S; Sammut IA; Appleton I
    J Pineal Res; 2011 Oct; 51(3):313-23. PubMed ID: 21605165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is melatonin ready to be used in preterm infants as a neuroprotectant?
    Biran V; Phan Duy A; Decobert F; Bednarek N; Alberti C; Baud O
    Dev Med Child Neurol; 2014 Aug; 56(8):717-23. PubMed ID: 24575840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin's efficacy in stroke patients; a matter of dose? A systematic review.
    Ramos E; Farré-Alins V; Egea J; López-Muñoz F; Reiter RJ; Romero A
    Toxicol Appl Pharmacol; 2020 Apr; 392():114933. PubMed ID: 32112789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
    Hardeland R
    Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin receptors mediate improvements of liver function but not of hepatic perfusion and integrity after hemorrhagic shock in rats.
    Mathes AM; Kubulus D; Weiler J; Bentley A; Waibel L; Wolf B; Bauer I; Rensing H
    Crit Care Med; 2008 Jan; 36(1):24-9. PubMed ID: 18090374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating promising preclinical neuroprotective therapies to human stroke trials.
    Cook DJ; Tymianski M
    Expert Rev Cardiovasc Ther; 2011 Apr; 9(4):433-49. PubMed ID: 21517728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin as a potential antihypertensive treatment.
    Simko F; Paulis L
    J Pineal Res; 2007 Apr; 42(4):319-22. PubMed ID: 17439547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis.
    Rosenstein RE; Pandi-Perumal SR; Srinivasan V; Spence DW; Brown GM; Cardinali DP
    J Pineal Res; 2010 Aug; 49(1):1-13. PubMed ID: 20492443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy.
    Witt-Enderby PA; Radio NM; Doctor JS; Davis VL
    J Pineal Res; 2006 Nov; 41(4):297-305. PubMed ID: 17014686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.
    Greenhalgh AD; Ogungbenro K; Rothwell NJ; Galea JP
    Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):681-95. PubMed ID: 21521135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin and the immune system in aging.
    Cardinali DP; Esquifino AI; Srinivasan V; Pandi-Perumal SR
    Neuroimmunomodulation; 2008; 15(4-6):272-8. PubMed ID: 19047804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modulatory role of melatonin on immune responsiveness.
    Carrillo-Vico A; Reiter RJ; Lardone PJ; Herrera JL; Fernández-Montesinos R; Guerrero JM; Pozo D
    Curr Opin Investig Drugs; 2006 May; 7(5):423-31. PubMed ID: 16729718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of melatonin for the treatment or prevention of obesity: an urgent need to include weight reduction as a secondary outcome in clinical trials of melatonin in obese patients with sleep disorders.
    Rastmanesh R; de Bruin PF
    Contemp Clin Trials; 2012 Jul; 33(4):574-5. PubMed ID: 22504344
    [No Abstract]   [Full Text] [Related]  

  • 19. Ramelteon: new drug. Insomnia: no role for risky placebos.
    Prescrire Int; 2008 Oct; 17(97):183-6. PubMed ID: 19534018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Melatonin in sleep rhythm disorders after cerebral stroke].
    Domzał TM; Kaca-Oryńska M; Zaleski P
    Pol Merkur Lekarski; 2000 Jun; 8(48):411-2. PubMed ID: 10967921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.